Global's Prime Stocks Possibly Trading Below Estimated Value In October 2025

As global markets grapple with renewed U.S.-China trade tensions and concerns over a prolonged U.S. government shutdown, investors are keeping a close watch on the potential impacts these factors may have on stock valuations and overall market sentiment. Amidst this uncertainty, identifying stocks that may be trading below their estimated value can offer opportunities for those looking to navigate the current economic landscape effectively.

Top 10 Undervalued Stocks Based On Cash Flows

Click here to see the full list of 509 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

ASTERASYSLtd (KOSDAQ:A450950)

Overview: ASTERASYS Co., Ltd specializes in manufacturing and selling medical equipment for hospitals and skincare devices for beauty clinics across various global markets, with a market cap of ₩481.59 billion.

Operations: The company generates revenue of ₩34.50 billion from its operations in manufacturing and selling medical and aesthetic devices across multiple international markets.

Estimated Discount To Fair Value: 20%

ASTERASYS Ltd is trading at ₩14,800, significantly below its estimated fair value of ₩18,509.89. The company's revenue and earnings are forecast to grow robustly at 31.7% and 41.7% per year respectively, outpacing the KR market averages. With a projected high return on equity of 40.5% in three years and strong non-cash earnings quality, ASTERASYS presents an attractive opportunity for investors focused on undervalued stocks based on cash flows.

• Our comprehensive growth report raises the possibility that ASTERASYSLtd is poised for substantial financial growth.
• Unlock comprehensive insights into our analysis of ASTERASYSLtd stock in this financial health report.

ACWA Power (SASE:2082)

Overview: ACWA Power Company, along with its subsidiaries, focuses on the investment, development, operation, and maintenance of power generation, water desalination, and green hydrogen production plants across Saudi Arabia, the Middle East, Asia, and Africa; it has a market capitalization of SAR179.83 billion.

Operations: The company's revenue segments include SAR1.90 billion from renewables and SAR5.29 billion from thermal and water desalination.

Estimated Discount To Fair Value: 39.7%

ACWA Power is trading at SAR 234.8, well below its estimated fair value of SAR 389.23, indicating potential undervaluation based on cash flows. The company's earnings and revenue are forecast to grow significantly faster than the Saudi Arabian market averages at 25% and 20.1% per year, respectively. However, debt coverage by operating cash flow remains a concern. Recent expansions in renewable energy projects may positively impact financials in the second half of 2025.

• Upon reviewing our latest growth report, ACWA Power's projected financial performance appears quite optimistic.
• Dive into the specifics of ACWA Power here with our thorough financial health report.

Beijing Chunlizhengda Medical Instruments (SEHK:1858)

Overview: Beijing Chunlizhengda Medical Instruments Co., Ltd. operates in the medical device industry, focusing on the production and sale of orthopedic implants and related surgical instruments, with a market cap of approximately HK$9.16 billion.

Operations: The company's revenue segment primarily consists of the manufacture and trading of surgical implants, instruments, and related products, amounting to CN¥913.32 million.

Estimated Discount To Fair Value: 24.8%

Beijing Chunlizhengda Medical Instruments is trading at HK$15.72, significantly below its estimated fair value of HK$20.91, reflecting potential undervaluation based on cash flows. The company's earnings are expected to grow 25.5% annually, surpassing the Hong Kong market's average growth rate of 12.7%, although revenue growth is slower than 20% per year but still above market averages. Recent half-year results show a strong performance with sales and net income increasing notably from the previous year.

• In light of our recent growth report, it seems possible that Beijing Chunlizhengda Medical Instruments' financial performance will exceed current levels.
• Get an in-depth perspective on Beijing Chunlizhengda Medical Instruments' balance sheet by reading our health report here.

Key Takeaways

• Navigate through the entire inventory of 509 Undervalued Global Stocks Based On Cash Flows here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com